Trastuzumab Combined with Irinotecan in Patients with HER2-Positive Metastatic Colorectal Cancer: A Phase II Single-Arm Study and Exploratory Biomarker Analysis

PURPOSE: The human epidermal growth factor receptor 2 (HER2) is an established therapeutic target for various kinds of solid tumors. HER2 amplification occurs in approximately 1% to 6% of colorectal cancer. In this study, we aimed to assess the efficacy and safety of trastuzumab in combination with...

Descripción completa

Detalles Bibliográficos
Autores principales: Xu, Ting, Wang, Xicheng, Xin, Ying, Wang, Zhenghang, Gong, Jifang, Zhang, Xiaotian, Li, Yanyan, Ji, Congcong, Sun, Yu, Zhao, Feilong, Huang, Depei, Bai, Yuezong, Li, Jian, Shen, Lin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Korean Cancer Association 2023
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10101806/
https://www.ncbi.nlm.nih.gov/pubmed/36550683
http://dx.doi.org/10.4143/crt.2022.1058

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10101806/
https://www.ncbi.nlm.nih.gov/pubmed/36550683
http://dx.doi.org/10.4143/crt.2022.1058

Ejemplares similares